1. Home
  2. MRK vs SRPT Comparison

MRK vs SRPT Comparison

Compare MRK & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merck & Company Inc. (new)

MRK

Merck & Company Inc. (new)

HOLD

Current Price

$118.77

Market Cap

268.7B

Sector

Health Care

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$17.64

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRK
SRPT
Founded
2000
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.7B
2.5B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
MRK
SRPT
Price
$118.77
$17.64
Analyst Decision
Buy
Hold
Analyst Count
17
29
Target Price
$125.59
$25.85
AVG Volume (30 Days)
7.1M
2.6M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
3.06%
N/A
EPS Growth
8.01
N/A
EPS
N/A
2.88
Revenue
$65,011,000,000.00
$2,198,237,000.00
Revenue This Year
$3.61
N/A
Revenue Next Year
$5.41
N/A
P/E Ratio
N/A
$5.99
Revenue Growth
1.31
15.58
52 Week Low
$75.40
$10.42
52 Week High
$125.14
$43.92

Technical Indicators

Market Signals
Indicator
MRK
SRPT
Relative Strength Index (RSI) 57.57 42.49
Support Level $112.49 $17.11
Resistance Level $124.57 $18.10
Average True Range (ATR) 2.55 0.77
MACD 0.94 -0.09
Stochastic Oscillator 64.89 28.85

Price Performance

Historical Comparison
MRK
SRPT

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: